2023年6月最新SCI影响因子数据已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | ANNALS OF ONCOLOGY ANN ONCOL （此期刊被最新的JCR期刊SCIE收录） LetPub评分 9.7
51人评分
我要评分
声誉 10.0 影响力 9.5 速度 9.7 | |||||||||||||||||||||
| 期刊ISSN | 0923-7534 | 微信扫码收藏此期刊 | ||||||||||||||||||||
| E-ISSN | 1569-8041 | |||||||||||||||||||||
| 2022-2023最新影响因子 （数据来源于搜索引擎） | 50.5 点击查看影响因子趋势图 | |||||||||||||||||||||
| 实时影响因子 | 截止2023年9月27日：21.33 | |||||||||||||||||||||
| 2022-2023自引率 | 1.00%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年影响因子 | 32.4 | |||||||||||||||||||||
| h-index | 210 | |||||||||||||||||||||
| CiteScore |
| |||||||||||||||||||||
| 期刊简介 | Annals of Oncology, the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, provides rapid and efficient peer-review publications on innovative cancer treatments or translational work related to oncology and precision medicine. Main focuses of interest include: systemic anticancer therapy (with specific interest on molecular targeted agents and new immune therapies), randomized trials (including negatives ones), top-level guidelines, and new fields currently emerging as key components of personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Radiotherapy, surgery and pediatrics manuscripts can be considered if they display a clear interaction with one of the fields above or are paradigm-shifting. | |||||||||||||||||||||
| 期刊官方网站 | http://annonc.oxfordjournals.org/ | |||||||||||||||||||||
| 期刊投稿网址 | http://www.oxfordjournals.org/our_journals/annonc/for_authors/submission_online.html | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足ANNALS OF ONCOLOGY的语言要求，还能让ANNALS OF ONCOLOGY编辑和审稿人得到更好的审稿体验，让稿件最大限度地被ANNALS OF ONCOLOGY编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | OXFORD UNIV PRESS, GREAT CLARENDON ST, OXFORD, ENGLAND, OX2 6DP | |||||||||||||||||||||
| 出版商 | Oxford University Press | |||||||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||
| 出版国家或地区 | ENGLAND | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Monthly | |||||||||||||||||||||
| 出版年份 | 1990 | |||||||||||||||||||||
| 年文章数 | 91点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 36.91% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 91.21% | |||||||||||||||||||||
| WOS期刊SCI分区 （ 2022-2023年最新版） | WOS分区等级：1区
| |||||||||||||||||||||
| 中科院《国际期刊预警 名单（试行）》名单 | 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2021年01月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2022年12月最新升级版） | 点击查看中科院SCI期刊分区趋势图
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月基础版） |
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月升级版） |
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2020年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0923-7534%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 很快,2-3周 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 较难 | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在ANNALS OF ONCOLOGY顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial Author: Tang, H.; Wang, H.; Fang, Y.; Zhu, J. Y.; Yin, J.; Shen, Y. X.; Zeng, Z. C.; Xiang, D. X.; Hou, Y. Y.; Du, M.; Lian, C. H.; Zhao, Q.; Jiang, H. J.; Gong, L.; Li, Z. G.; Liu, J.; Xie, D. Y.; Li, W. F.; Chen, C.; Zheng, B.; Chen, K. N.; Dai, L.; Liao, Y. D.; Li, K.; Li, H. C.; Zhao, N. Q.; Tan, L. J. Journal: ANNALS OF ONCOLOGY. 2023; Vol. 34, Issue 2, pp. 163-172. DOI: 10.1016/j.annonc.2022.10.508 PubMed DOI |
| 2. | Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study Author: Rha, S. Y.; Wyrwicz, L. S.; Weber, P. E. Y.; Bai, Y.; Ryu, M. H.; Lee, J.; Rivera, F.; Alves, G. V.; Garrido, M.; Shiu, K. -k.; Fernandez, M. Gonzalez; Li, J.; Lowery, M.; Cil, T.; Cruz, F. J. S. M.; Qin, S.; Yin, L.; Bordia, S.; Bhagia, P.; Oh, D-y. Journal: ANNALS OF ONCOLOGY. 2023; Vol. 34, Issue 3, pp. 319-320. DOI: 10.1016/j.annonc.2023.01.006 DOI |
| 3. | Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study Author: Psyrri, A.; Fayette, J.; Harrington, K.; Gillison, M.; Ahn, M. -J.; Takahashi, S.; Weiss, J.; Machiels, J. -P.; Baxi, S.; Vasilyev, A.; Karpenko, A.; Dvorkin, M.; Hsieh, C. -Y.; Thungappa, S. C.; Segura, P. P.; Vynnychenko, I.; Haddad, R.; Kasper, S.; Mauz, P. -S.; Baker, V.; He, P.; Evans, B.; Wildsmith, S.; Olsson, R. F.; Yovine, A.; Kurland, J. F.; Morsli, N.; Seiwert, T. Y. Journal: ANNALS OF ONCOLOGY. 2023; Vol. 34, Issue 3, pp. 262-274. DOI: 10.1016/j.annonc.2022.12.008 PubMed DOI |
| 4. | Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC Author: Mok, T. S. K.; Lopes, G.; Cho, B. C.; Kowalski, D. M.; Kasahara, K.; Wu, Y. -l.; de Castro Jr, G.; Turna, H. Z.; Cristescu, R.; Aurora-Garg, D.; Loboda, A.; Lunceford, J.; Kobie, J.; Ayers, M.; Pietanza, M. C.; Piperdi, B.; Herbst, R. S. Journal: ANNALS OF ONCOLOGY. 2023; Vol. 34, Issue 4, pp. 377-388. DOI: 10.1016/j.annonc.2023.01.011 PubMed DOI |
| 5. | Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Author: Hendriks, L. E.; Kerr, K. M.; Menis, J.; Mok, T. S.; Nestle, U.; Passaro, A.; Planchard, D.; Peters, S.; Smit, E. F.; Solomon, B. J.; Veronesi, G.; Reck, M.; SMO Guidelines Comm Journal: ANNALS OF ONCOLOGY. 2023; Vol. 34, Issue 4, pp. 358-376. DOI: 10.1016/j.annonc.2022.12.013 PubMed DOI |
| 6. | Biological background of the genomic variations of cf-DNA in healthy individuals. Author: Liu J1,2, Chen X3, Wang J4,5, Zhou S1, Wang CL1, Ye MZ6, Wang XY1, Song Y1, Wang YQ1, Zhang LT1, Wu RH1, Yang HM4,5, Zhu SD4, Zhou MZ6, Zhang XC7, Zhu HM3, Qian ZY3. Journal: Ann Oncol. 2019 Mar 1;30(3):464-470. doi: 10.1093/annonc/mdy513. PubMed DOI |
| 7. | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Author: Muro K1, Van Cutsem E2, Narita Y1, Pentheroudakis G3, Baba E4, Li J5, Ryu MH6, Zamaniah WIW7, Yong WP8, Yeh KH9,10, Kato K11, Lu Z12, Cho BC13, Nor IM14, Ng M15, Chen LT16, Nakajima TE17, Shitara K18, Kawakami H19, Tsushima T20, Yoshino T18, Lordick F21,22, Martinelli E23, Smyth EC24, Arnold D25, Minami H26, Tabernero J27, Douillard JY28. Journal: Ann Oncol. 2019 Jan 1;30(1):19-33. doi: 10.1093/annonc/mdy502. PubMed DOI |
| 8. | Virtual microdissection in the molecular subtyping of head and neck squamous carcinoma-a 'Virtual Reality' of the tumor microenvironment? Author: Ma BBY1. Journal: Ann Oncol. 2019 Jan 1;30(1):8-10. doi: 10.1093/annonc/mdy516. PubMed DOI |
| 9. | Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Author: Wu YL1, Planchard D2, Lu S3, Sun H4, Yamamoto N5, Kim DW6, Tan DSW7, Yang JC8, Azrif M9, Mitsudomi T10, Park K11, Soo RA12, Chang JWC13, Alip A14, Peters S15, Douillard JY16. Journal: Ann Oncol. 2019 Feb 1;30(2):171-210. doi: 10.1093/annonc/mdy554. PubMed DOI |
| 10. | HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. Author: Wang Y1, Jiang T1, Qin Z2, Jiang J3, Wang Q3, Yang S1, Rivard C4, Gao G1, Ng TL4, Tu MM5,6, Yu H4, Ji H1,2, Zhou C1, Ren S1,4, Zhang J7, Bunn P4, Doebele RC4, Camidge DR4, Hirsch FR4. Journal: Ann Oncol. 2019 Mar 1;30(3):447-455. doi: 10.1093/annonc/mdy542. PubMed DOI |
|
|
  | |
|
以上SCI期刊相关数据和信息来源于网络，仅供参考。
投稿状态统计： 我要评分： | |
同领域作者分享投稿经验：共4条 （包含回复） |
我来分享 |
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2023 中国: LetPub上海分公司 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960
增值电信业务经营许可证：沪B2-20211595
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦2103室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451
安全保密
